"TFS CORP (TFC) IS A BUY AT $2.80
Positive first half results for TFS, a sandalwood producer, will be reliant on the timing of new establishment sales. UBS sees the major catalysts for TFS at its first half yearly results to be: reaffirming expectations of a 10-fold Indian Sandalwood production increase in mid-2016 (likely at 1H16 result), and providing an update on the sales of the first pharmaceutical product (Benzac acne treatment).
Beyond this result, UBS sees potential catalysts from: additional pharmaceutical products using Sandalwood Oil announced (likely over 2016), andrefinancing the company's USD Notes (likely in FY17E). UBSe: Cash EBITDA of $9.5m, Reported NPAT $11m, DPS 0cps